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Aims Angiographic studies on the natural course of both
focal and diffuse coronary atherosclerosis have not been
performed before, but can both be assessed by quantitative
coronary angiography. The objective of this study was to
describe the natural course of focal and diffuse coronary
atherosclerosis over time.
Methods and results In 129 patients with mild coronary
artery disease, but not on lipid-lowering medication, three
coronary angiograms were made each 2 years apart. Nine
hundred and sixty five angiographically diseased and non-
diseased segments were analysed by quantitative coronary
angiography. Mean lumen diameter and minimal lumen
diameter were used as measures of diffuse and focal
coronary atherosclerosis.
Mean lumen diameter and minimum lumen diameter de-
creased by 002 and 003 mm per year. The rate of progress-
sion was similar in the angiographically non-diseased, as in
the mildly and moderately diseased segments. Progression
of diffuse coronary atherosclerosis was largest in severely
stenosed lesions (percentage diameter stenosis >50%) and
in the right coronary artery with a loss of 019 mm and
016 mm in mean lumen diameter. Progression of focal
disease was most prominent in new and mild lesions and the
right coronary artery, with a decrease in minimum lumen
diameter of 0-34 mm and 0-22 mm. In most subgroups,
progression occurred gradually over time. On a per segment
level, progression and the occurrence of new lesions
occurred in 4-4% and 4-2%. Regression and disappearance
of a lesions was found in 23% and 1-9%. On a per patient
level, 36% were progressors, 12% had a mixed response,
36% were stable, and 16% were regressors.
Conclusion Diffuse and focal coronary atherosclerosis
progressed at the same rate in the first and second 2 years in
stenosed and non-stenosed segments. The rate of coronary
atherosclerosis progression was small, but was higher for
focal than for diffuse disease. A minority of lesions pro-
gressed and spontaneous regression was rare.
(Eur Heart J 1997; 18: 1081-1089)
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Introduction
Several prospective studies on the angiographic course
of coronary atherosclerosis using quantitative coronary
angiography have been published, but none of these
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included three angiograms11 14'. The majority of these
studies focussed on lesion changes and only a few
assessed changes in angiographically non-diseased cor-
onary segments17'81"-13141. Four other studies1'5"181 used
serial coronary angiography (three or more angiograms)
which described angiographic changes over time. In
three of these investigations, however, the coronary
angiograms were assessed visually. We performed a
prospective quantitative coronary angiographic study
with three serial coronary angiograms over 4 years, in
patients with mild to moderate coronary artery disease
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not treated by lipid-lowering drugs or revascularization
procedures. We assessed the angiographic evolution of
diffuse and focal coronary atherosclerosis in non-
stenosed (angiographically normal) and stenosed
coronary segments.
Methods
Patients
The patients constituted the placebo group of an angi-
ographic trial, (the MAAS, Multicenter Anti-Atheroma
Study), which compared simvastatin 20 mg daily with
placebo, and has been described and reported else-
where'19'201. Both male and female patients were enrolled
from 11 clinics from six European countries. At angi-
ography, in each participant, at least two coronary
segments were visibly atherosclerotic, but they did not
require revascularization. The patients were in a stable
clinical condition, and no lipid-lowering drugs were
allowed. Total cholesterol was between 5-5 and
8 0 m m o l . l ~ ' , and triglycerides were below
4 mmol. 1 ~ '. All patients were followed for 4 years.
Clinical events, death, myocardial infarction, unstable
angina pectoris, percutaneous transluminal coronary
angioplasty and coronary bypass surgery were evaluated
centrally by a clinical events committee.
Coronary angiography and quantitative
coronary analysis
Coronary angiography was performed according to
standards for quantitative analysis at baseline and after
2 and 4 years. Prior to angiography, patients received
5 mg isosorbide dinitrate sublingually to induce stand-
ardized vasodilation. In each projection, the catheter tip
not filled with contrast medium was filmed and sent with
the angiogram to the quantitative coronary angiography
core laboratory for calibration. All relevant aspects of
the angiography procedure (sequence of injections, pro-
jections, angulation and rotation, type and size of the
catheters) were recorded on a case report form to enable
exact repetition of the procedure at the 2- and 4-year
follow-up.
Analyses of the angiograms were performed
centrally in a quantitative coronary angiography core
laboratory using the Coronary Angiography Analysis
System (CAAS)'2'1. From the baseline angiograms,
orthogonal projections of 11 large proximal coronary
segments, both angiographically diseased and non-
diseased, were selected'221: right coronary artery: proxi-
mal (1), mid (2), distal (3); left main coronary artery (5);
left anterior descending artery: proximal (6), mid (7),
distal (8); left cirumflex artery: proximal (11), obtusis
marginalis (12), distal (13), posterior lateralis (14)[23].
Totally occluded segments and segments that had pre-
viously undergone percutaneous transluminal coronary
angioplasty were not included in the baseline selection.
When percutaneous transluminal coronary angioplasty
was performed, the pre-angioplasty analysis of the di-
lated coronary segment was used at 2 and 4 years as
appropriate. If no pre-angioplasty analysis was present,
the segment was excluded. For all segments, mean lumen
diameter (mm) and segment length (mm) were calcu-
lated. In addition, minimum lumen diameter (mm) and
percentage diameter stenosis (%) were estimated for all
angiographically diseased segments. In the subgroup of
segments with a narrowing of at least 20% in a projec-
tion in all three angiograms, additional stenosis par-
ameters were computed: interpolated reference or
normal vessel diameter (mm), stenosis length (mm),
and plaque area (mm2) which is calculated as the
area between the interpolated normal vessel contour
constructed by the computer and the measured vessel
contour at the site of a stenosis1211. The plaque area
represents the longitudinal cross-sectional area of the
plaque that encroaches on the vessel lumen. The avail-
able multiple matched projections were used for the
assessment of change over time1241. In the present study,
only the most severe stenosis in a segment was taken into
account. New occlusions at 2 and 4 year follow-up were
assigned a mean and minimum lumen diameter of 0 mm
and a percentage diameter stenosis of 100%.
Angiographic definitions
The mean lumen diameter of all segments was inter-
preted as the measure of diffuse coronary atheroscler-
osis, and the minimum lumen diameter of stenosed
segments as the primary measure of focal atheroscler-
osis'221. A negative change in diameter is a decrease in
vessel lumen and therefore indicates progresssion of
atherosclerosis. A segment was considered angiographi-
cally diseased when there was a percentage diameter
stenosis > 20% at baseline or at follow- up. Progression
was defined as an increase > 15% in percentage diameter
stenosis, regression as a decrease of 15%. At follow-up,
segments were classified as (1) non-diseased, (2) new
lesion, (3) stable lesion, (4) progressed lesion, (5) re-
gressed lesion, (6) disappeared lesion. From this classi-
fication of segments, patients were classified as (1)
progressor: at least 1 segment progressed, (2) mixed
responder: both progressed and regressed segments, (3)
stable: only stable segments, (4) regressor: at least 1
segment regressed. For change in diffuse coronary
atherosclerosis, segments and patients were classified
according to a change in mean lumen diameter of
0-4 mm, a cutoff point also used for change in minimum
lumen diameter'21.
Statistical aspects
Baseline characteristics are presented as numbers and
percentages and as mean ± SD. Quantitative coronary
angiography measurements at baseline and follow-up
are reported as mean ± SE. The 95% confidence inter-
vals can be calculated as mean ± 1-96 x SE. Changes
over time were evaluated by paired analysis of variance.
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A /"-value <0-05 was considered statistically significant.
All analyses are presented on a per segment basis. To
test whether dependence of segments within patients
influenced the results, a nested analysis within patients
was performed. Since this yielded results similar to
the analysis per segment, only the latter is reported.
Angiographic changes are reported for the group as a
whole, stratified according to the severity of disease
at baseline: percentage diameter stenosis <20% (non-
diseased), >20%-<35% (mildly diseased), >35%-<50%
(moderately diseased), >50% (severely diseased), and
stratified according to the coronary artery. For each
subgroup, changes are reported for diffuse coronary
atherosclerosis (mean lumen diameter) and focal disease
(minimum lumen diameter).
Results
The study population consisted of 188 patients with an
approved baseline angiogram. For 59 patients no com-
plete angiographic follow-up was available, thus 129
patients (69%) had both a 2- and a 4-year follow-up
angiogram. Reasons for not having follow-up angiogra-
phy were death (11 patients), intercurrent coronary
bypass surgery (9 patients), insufficient quality for quan-
titative analysis (1 patient), and refusal (38 patients). In
the 129 patients with complete angiographic follow-up,
1753 projections of 965 segments were analysed, of
which 614 were angiographically diseased. In 541 pro-
jections of 341 segments, stenosis parameters were cal-
culated. The mean total length of segments per patient
was 164-2 mm (±440) . This did not change signifi-
cantly at 2- and 4-year follow-up. Of the 129 patients
with complete angiographic follow-up, one third had a
history of myocardial infarction and half had previously
undergone percutaneous transluminal coronary angi-
oplasty. Half of the patients had no significant disease
(a diameter stenosis of >50%) at visual assessment
(Table 1).
Clinical events
Of the initial 188 patients, 137 (73%) had no clinical
event during the 4-year follow-up. There were 11 (5-9%)
deaths of which 5 were cardiac (2 fatal myocardial
infarction, 1 sudden death and 2 congestive heart fail-
ure). Furthermore, 5 (2-7%) non-fatal myocardial infarc-
tions occurred, and 18 (9-6%) patients were hospitalized
for unstable angina. There were 38 (20-2%) revasculari-
zation procedures: 16 coronary bypass surgery and 22
percutaneous transluminal coronary angioplasty.
Quantitative coronary angiography:
development of diffuse and focal coronary
atherosclerosis
Distribution of angiographic changes
Figure 1 shows the distribution of angiographic changes
on a per segment basis between baseline and 4 years.
Table 1 Baseline characteristics for 129 patients with
complete angiographic follow-up
Age (years)
Males
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Previous MI
Previous PTCA
Current angina
Current smoker
Vessel disease (visual assessment*)
None
One
Two
Three
Total cholesterol
LDL-C
HDL-C
Triglycerides
Long-acting nitrate
Beta-blocker
Calcium antagonist
ACE inhibitor
Aspirin
55-5
117
132
80
42
67
112
22
59
44
19
7
6-40
4-47
1-11
1-80
48
54
57
18
70
±6-6
91%
± 15-0
±8-0
33%
52%
70%
17%
46%
34%
15%
5%
± 0 81
±0-79
±0-29
±0-84
37%
42%
44%
14%
54%
Values are means ± standard deviation; MI = myocardial infarc-
tion; PTCA = percutaneous transluminal coronary angioplasty;
LDL-C = low density lipoprotein cholesterol; HDL-C=high density
lipoprotein cholesterol; ACE = angiotensin converting enzyme.
*A vessel with a stenosis >50% was considered diseased.
Most segments do not change significantly over 4 years.
For mean lumen diameter 12% progressed, 81% were
stable and 7% of segments regressed. For minimum
lumen diameter 12% of angiographically diseased seg-
ments progressed, 79% were stable and 9% regressed.
Diseased and non-diseased segments
Table 2 shows the quantitative coronary angiography
results at baseline, 2 and 4 years. Mean lumen diameter,
a measure of diffuse atherosclerosis, decreased by
006mm and 008 mm and 2 and 4 years, respectively
(Table 3). Both the disease progression from baseline to
2, and from 2 to 4 years were significant. These changes
represent a decrease of mean vessel diameter of 2-8%
over 4 years. The magnitude of loss in mean lumen
diameter was similar in both the non-diseased and
mildly diseased segments. Progression in diffuse disease
was approximately three times greater in the moderately
and severely diseased segments.
Stratification for coronary artery and severity of disease
Decrease in vessel lumen was most prominent in the
right coronary artery, being 5 times as great as in the left
anterior descending coronary artery. Minimum lumen
diameter, a measure of focal atherosclerosis, decreased
by 006 mm and 012 mm after 2 and 4 years, respect-
ively. This is a decrease of 60% over 4 years. Progres-
sion of focal atherosclerosis was greatest for the lesions
non-stenosed at baseline: a decrease of 0-34 mm in
minimum lumen diameter and an increase of 12-4% in
percentage diameter stenosis. The rate of progression
decreased with the severity of the lesions at baseline.
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Figure 1 Cumulative distribution curves for mean lumen diameter, minimum lumen diameter, percentage
diameter stenosis, and plaque area (of changes between baseline and 4 years) with cut-off points for segment
and stenosis change indicating progression of coronary atherosclerosis, stable disease, and regression of
coronary atherosclerosis.
Severely diseased lesions at baseline showed no progres-
sion, but a small and non-significant improvement. As
with diffuse disease, progression was greatest in the right
coronary artery with a loss in minimum lumen diameter
of 0-22 mm and an increase of percentage diameter
stenosis of 6-1%.
Stenosis parameters
Table 2 also shows the results for the subgroup of 341
segments in which stenosis parameters were calculated at
baseline and at 2 and 4 years. The changes in lesion
length and plaque area were in accordance with the
changes in minimum lumen diameter. In the combined
mildly and moderately diseased segments, minimum
lumen diameter decreased by 0-13 mm, the percentage
diameter stenosis increased by 14-5%, the length of the
stenosis by 0-43 mm, and the plaque area by 0-58 mm2.
There was a small but significant decrease of 005 mm
in the normal segment diameter, suggesting that pro-
gression of diffuse atherosclerosis occurred in the
non-stenosed parts of these segments.
Changes over time
The overall changes over time are depicted in Fig. 2.
Diffuse atherosclerotic progression was more pro-
nounced in the first 2 years in the non-diseased and
severely diseased segments. For the segments with mild
and moderate disease (percentage diameter stenosis
between 20% and 50%), loss in vessel lumen developed
mostly in the last 2 years of the study. In the right
coronary artery, progression was twice as great in the
second half of the study, with a decrease of 0-10 mm and
0-22 mm in minimum lumen diameter in the first and
second half of the study, respectively. In the left anterior
descending coronary artery, progression occurred more
gradually, whereas the left circumflex artery showed
marked progression in the first half and some regression
in the second half of the study.
Categorical changes
Half of the segments remained non-diseased after 2 and
4 years (Table 4). Progression was seen in 6% and 9%
and regression in 3% and 4% of segments after 2 and 4
years, respectively. After 2 years 10 (1-0%) new total
occlusions occurred and after 4 years 16 (1-7%) in 15
patients (11%). One total occlusion at 2 years re-opened
at 4 years. In these 15 patients, in whom total occlusion
developed, two suffered an overt clinical myocardial
infarction. The classification per patient showed that
after 4 years 48% of the patients had progressed or had
a mixed response, which was 38% at 2 years. The
percentage of regressors increased from 9% at 2 years to
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Table 2 Quantitative angiographic measurements at baseline, 2 year and 4 year
follow-up
Baseline 2 years 4 years
mean SE mean SE mean SE
All segments (n=965)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Length of stenosis (mm)
Plaque area (mm2)
Non-diseased segments at baseline (n=489)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Mildly diseased segments at baseline (n = 295)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Length of stenosis (mm)
Plaque area (mm2)
Moderately diseased segments at baseline (n= 146)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Length of stenosis (mm)
Severely diseased segments at baseline (n = 35)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Length of stenosis (mm)
Plaque area (mm2)
Right coronary artery (n = 274)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Left main coronary artery (n= 100)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Left anterior descending artery (n = 309)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
Left circumflex artery (n = 282)
Mean lumen diameter (mm)
Minimum lumen diameter (mm)
Percentage diameter stenosis (%)
2-85 ± 0-03
1-93 ±002
29-62 ± 0-47
6-25 ±016
4-99 ± 0-20
318 ±004
2-39 ± 0 05
15-87 ±0-26
2-54 ± 0-04
1 93 ± 0 0 3
27-10 ±0-24
6-38 ± 0-24
402 ± 0-23
2-50 ±0-05
1-66 ±004
41-39 ±0-37
603 ± 0-23
2-36 ±011
1-23 ± 0 0 7
56-39 ± 1 02
6-59 ±0-58
7-24 ± 0 92
3-07 ± 0 04
2-20 ± 005
29-32 ±0-93
4-13 ±002
2-62 ±014
21-90 ± 11-26
2-51 ±0-04
1-82 ± 0 0 3
27-68 ± 0-70
2-55 ± 0-04
1-76 ±0-04
31-19 ± 0-81
2-79 ± 003
1-87 ± 0 0 3
31-59 ±0-58
6-52 ± 0 1 7
5-44 ± 0-26
311 ± 0 0 5
2-16 ±0-05
25-33 ±0-98
2-53 ± 0-04
1-91 ± 0 0 3
27-68 ±0-54
6-47 ± 0-26
4-77 ±0-39
2-45 ± 006
1-66 ±004
39-96 ±1 17
6-57 ±0-24
2-12±0-19
1-27 ± 012
54-73 ±3-55
6-57 ±0-61
6-81 ±0-82
3-01 ±005
211 ±0-05
32-44± 1-12
4-08 ± 008
2-63 ±012
23-53 ±9-26
2-49 ± 004
1-81 ±004
28-40 ±0-75
2-46 ± 0-04
1 68 ±004
34-36±110
2-77 ± 0-03
1-82 ± 0 0 3
32-92 ±0-64
6-63 ± 0 1 7
5-51 ±0-22
3-10 ±0-05
206 ± 005
28-28 ± 1-20
2-48 ± 0-04
1-86 ±0-03
28-99 ± 0-69
6-68 ±0-25
5-16±0-31
2-37 ±0-07
1 -61 ±005
40-21 ± 1-40
6-58 ± 0-24
2-17 ±0-18
1-29 ±011
53-99 ±3-39
6-65 ±0-67
6-66 ± 0-89
2-91 ± 0 0 5
1 99 ± 0 0 5
35-41 ± 1-37
402 ± 008
2-44 ± 007
25-48 ±3-81
2-47 ± 0-04
1-75 ±0-03
29-71 ±0-78
2-50 ± 0 0 5
1-69 ± 0 0 4
3414± 115
SE = standard effort; angiographically non-diseased = percentage diameter stenosis <20%; mildly
diseased = percentage diameter stenosis >20%-<35%; moderately diseased = percentage diameter
stenosis >35%-<5O%; severely diseased = percentage diameter stenosis >50%.
16% at 4 years. When, as a measure of diffuse athero-
sclerosis, the criterion of 0-4 mm change in mean lumen
diameter was applied, then 27% of the patients pro-
gressed, 10% had a mixed response, 46% were stable and
19% regressed.
Discussion
The findings show that coronary atherosclerosis pro-
gressed gradually over 4 years, but that the rate of
progression of focal atherosclerosis was twice as great as
for diffuse disease. Progression was larger in severely
diseased segments and in the right coronary artery.
Angiographic changes
The extent of progression was small, with a loss of 002
(0-7%) mm and 0-03 mm (1-5%) per year for mean and
minimal lumen diameter as measures for diffuse and
focal atherosclerosis, respectively. The loss in vessel
lumen size in our study was smaller than that found in
other angiographic trials (Table 5). Apart from the
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Table 3 Changes at 4 years stratified for severity of disease at baseline and for vessel
Severity of disease
Non-diseased Mildly diseased Moderately diseased Severely diseased
Mean lumen diameter (mm)
Minimal lumen diameter (mm)
- 007 ± 002
- 0-34 ± 005
RCA
- 006 ± 002
• 0-07 ± 002
-0-13 ±0-05
- 0 0 5 ±0-03
Coronary vessel
LM LAD
— 019 ± 0-11
0-06 ± 008
LCX
Mean lumen diameter (mm) - 0 1 6 ±004 - 0 11 ±006
Minimal lumen diameter (mm) - 022 ± 004 - 0-18 ± 009
- 003 ± 002
- 007 ± 002
- 005 ± 0-03
- 007 ± 003
Values are means ± SE; non-diseased = percentage diameter stenosis <20%, mildly diseased = percentage diameter stenosis >20%-<35%;
moderately diseased = percentage diameter stenosis >35%-<50%; severely diseased = percentage diameter stenosis >50%. RCA = right
coronary artery; LM = left main; LAD = left anterior descending; LCX = left circumflex.
— Minimum lumen diameter
g
o
l
&
ca
6
_ Percentage diameter stenosis
Plaque cross-sectional area
Figure 2 Changes over time from baseline to 2- and 4-year follow-up for mean lumen diameter,
minimum lumen diameter, percentage diameter stenosis, and plaque area.
differences between the patients included, this might be
caused by the fact that we used the average of two
orthogonal projections instead of one projection in
which the stenosis was most severe. Furthermore,
we selected coronary segments at baseline and not by
inspection of the baseline and follow-up angiogram
together, so that we included segments that showed no
visibly assessed changes.
We have shown that the rate of progression of
focal atherosclerosis is similar in angiographically non-
diseased segments as in the mildly and moderately
diseased sections of the coronary tree. This finding
supports the hypothesis that assessment of lesion change
alone is not sufficient in describing progression of
coronary atherosclerosis. Only when the change in
mean lumen diameter of all coronary segments, angio-
graphically diseased and non-diseased, is measured,
is the process of atherosclerosis change described
completely1221.
The loss in vessel lumen was largest in the
right coronary artery, as was found by Jost et alP6\
The progression of diffuse atherosclerosis was most
Eur Heart J. Vol. 18, July 1997
 at Erasm
us University Rotterdam
 on July 2, 2010
e
u
rheartj.oxfordjournals.org
D
ow
nloaded from
 
Evolution of coronary atherosclerosis . 1087
Table 4 Categorical classification of change between
baseline, 2- and 4-year follow-up
Segment classification
(n = 965)
Progression of lesion
New lesion
Stable lesion
Regression of lesion
Disappeared lesion
Non-diseased segment
Patient classification
(n=129)
Progressor
Mixed responder
Stable
Regressor
2 years
Number
30
30
377
20
9
499
39
10
68
12
' (%)
(31)
(31)
(391)
(2-1)
(0-9)
(51 7)
(30-2)
(7-8)
(52-7)
(9-3)
4 years
Number
42
40
354
22
18
489
47
15
47
20(15-5)
(%)
(4 4)
(4-2)
(36-7)
(2-3)
(1-9)
(501)
(36-4)
(116)
(36-4)
prominent in the moderately and severely diseased seg-
ments, — 0-12 mm and —019 mm, respectively. The
minimum lumen diameter in these subgroups, however,
did not change significantly so that the segments con-
taining the more severe lesions only showed progression
of diffuse disease. The progression of focal disease
appeared to be largest in the segments with a percentage
diameter stenosis <20% at baseline, suggesting that
progression of focal atherosclerosis is more prominent in
angiographically new lesions that begin to encroach on
the vessel lumen.
Most subgroups showed gradual progression of
both diffuse and focal atherosclerosis over time. How-
ever, segments located in the left circumflex artery
mainly progressed in the first 2 years, and segments
in the left anterior descending coronary artery between
2 and 4 years. The categorical classification of
progression/regression per segment showed that 87% of
segments did not change substantially over 4 years and
that only 1 out of 12 lesions progressed and 1 out of 25
regressed. For the per patient classification, however,
changes were more pronounced, with 36% of patients
stable and 48% progressors or mixed repondes. There
was a gradual worsening of coronary disease over
time in both the per segment and the per patient
classification.
Limitations of the study
The results of our study were biased, as in all angio-
graphic trials'251, since follow-up angiography was not
available in patients who had a clinical event or refused
angiography, which in some cases might be related to
their clinical status. The rate of progression found will
therefore underestimate the actual tempo of atheroscler-
osis progression. We only included patients with proven
coronary artery disease of a severity not requiring
revascularization and with moderately elevated choles-
terol levels. Studies on the angiographic course of cor-
onary atherosclerosis in patients with or without severe
disease are not feasible since it is unethical to perform
angiography in the former and to withhold therapy in
the latter.
Angiographic methods
The use of validated quantitative coronary analysis
techniques has become mandatory in assessing coronary
atherosclerosis change from cinangiograms[22]. We used
orthogonal multiple matched views1241 which is different
from other studies in which only the projection in which
the stenosis was most severe was used[101. Our method
will therefore be more specific though less sensitive
to angiographic changes of the lumen. The selection
of coronary segments was made at baseline where,
when possible, orthogonal projections of 11 proximal
Table 5 Overview of guantitative coronary angiography studies with changes per
year
Study
FATS'41
MARS191
STARS'71
CCAIT"0'
SCRIP1"1
The present study
HARP'8121
PLAC I"3'
REGRESS1""
BECAIT"81
Overall*
Number
of patients
42
124
24
146
127
129
39
157
327
39
1154
Change MLD
(mm/year)
- 0020
- 0030
- 0053
- 0 0 4 5
- 0 0 4 5
- 0029
- 0 0 4 8
- 0050
- 0 0 4 5
- 0034
- 0039
Change DS
(%/year)
0-8
11
1-9
11
0-7
0-8
0-8
11
0-9
10
Change MD
(mm/year)
- 0 0 4 3
- 0027
- 0020
- 0037
- 0 0 4 0
- 0050
- 0 0 1 6
- 0036
MLD = minimum lumen diameter; DS = percentage diameter stenosis; MD = mean lumen diameter;
*weighted mean.
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segments were taken. Other investigators selected frames
for quantitative analysis at the end of the study with
both the baseline and follow-up angiograms avail-
able'91 0 J 7 1. The latter method of selection will result in a
bias towards projections and segments that are changed
and might therefore result in an over-estimation of the
rate of atherosclerotic change.
Clinical relevance
The rate of progression of coronary atherosclerosis
measured by quantitative coronary angiography was
small. Combining the information of the prospective
angiographic trials yielded an annual loss of 004 mm in
minimum lumen diameter, and a loss of 003 mm in
mean lumen diameter. However, all angiographic
studies were short relative to the time course of coronary
atherosclerosis1271, and one should keep in mind that
when this progression rate is taking place over 10 to 20
years, important reductions in vessel lumen will occur.
Although the angiographic changes are small, in two
prospective studies, one analysed visually [28) and the
other using quantitative coronary angiography1291 the
small angiographic changes are shown to be clinically
important because they are predictive of subsequent
clinical coronary events; similarly the absence of angio-
graphic progression was predictive of an uneventful
course.
Conclusion
The rate of angiographic progression of coronary
atherosclerosis in this cohort of patients with mild
coronary artery disease was relatively small and more
prominent in focal than in diffuse disease, with an
annual loss of 0-03 mm in minimum and 002 mm in
mean lumen diameter, respectively. Only a small minor-
ity of lesions progressed and few new lesions developed.
The distribution of progressed lesions, however, was
equally distributed over patients, so that the number of
patients classified as progressors was substantial. Spon-
taneous regression was rare both on a segmental as on a
patient level. Serial quantitative angiography showed
that diffuse and focal coronary atherosclerosis gradually
progressed over time in non-stenosed and stenosed
coronary segments.
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